
A study evaluating eradication of methicillin-resistant Staphylococcus aureus (MRSA) by fluoroquinolones shows that the commercially available preparation of gatifloxacin 0.3% (Zymar, Allergan) has superior bactericidal activity compared with the commercially available preparation of moxifloxacin 0.5% (Vigamox, Alcon). Gatifloxacin was more active than moxifloxacin alone, and its activity was enhanced by the presence of the preservative benzalkonium chloride.
